E-nitiate Biopharmaceuticals

Focus: E-nitiate is an early-stage Chinese small molecule biotech focused on immunology, founded in 2022 and currently in Series A funding stage. The company operates from Hangzhou with a lean development footprint targeting inflammatory skin conditions.

Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES A

Open Jobs

About E-nitiate Biopharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow E-nitiate Biopharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

0.1% QY211 Gel or placebo

Atopic Dermatitis

Phase 1

Clinical Trials (1)

NCT05843422A First-in-Human Study of QY211 Gel in Adult Subjects

Phase 1

Help build intelligence for E-nitiate Biopharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to shape drug development strategy at a Series A stage company with 5 active clinical programs across Phase 1-3
Focus on immunology and dermatology represents high-value therapeutic areas with significant unmet need in atopic dermatitis
Early-stage environment offers accelerated career progression and direct impact on clinical development decisions

Watch Out For

Zero active job postings suggest limited near-term hiring and possible resource constraints despite clinical activity
Pre-revenue status with no disclosed funding amounts creates uncertainty around cash runway and long-term viability
Earliest company founding date (2022) means minimal track record of regulatory success or clinical advancement beyond Phase 1

Generated by Claude from E-nitiate Biopharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

QY101 ointment or vehicle

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT05429177A First-in-Human Study of QY101 Ointment in Adult Subjects

Phase 1

2mg QY201 tablets or 2mg QY201 placebo,BID

Atopic Dermatitis

Phase 1/2

Clinical Trials (1)

NCT05525715A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

Phase 1/2

QY101Placebo/QY101 ointment

Psoriasis

Phase 2

Clinical Trials (1)

NCT06170840A Study of QY101 Ointment in Subjects With Plaque Psoriasis

Phase 2

10mg QY201 Placebo tablet

Atopic Dermatitis (AD)

Phase 3

Clinical Trials (1)

NCT07180511A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2022

Portfolio: 5 clinical trials

Top TAs: Immunology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Immunology

4 pipeline

Marketed

Pipeline